Analyst firms · Raymond James · HAE

Raymond James HAE price target and rating history

Haemonetics Corporation (HAE) · Health Care

Raymond James rates Haemonetics Corporation (HAE) Outperform with a $78 price target, as of its latest action on Aug 11, 2025. It has published 5 rating actions on HAE since August 2021, including 1 upgrade and 1 downgrade. Across 4 firms with a HAE price target in the last 12 months, the median target is $106.

Current rating
Outperform
Price target
$78
Median target, all firms
$106
Actions on HAE
5

Raymond James price target on HAE

$120$93$6620222023202420252026
Raymond James price target on HAE, each point a stated target, August 2021 to August 2025.

Every Raymond James rating on HAE

How other firms rate HAE

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
JefferiesBuy$150Nov 13, 2026
CitigroupBuy$123Sep 17, 2026
BofA SecuritiesBuy$80May 22, 2026
Barrington ResearchOutperform$89May 12, 2026
NeedhamHoldDec 15, 2025

Questions about Raymond James and HAE

What is Raymond James's price target for HAE?
Raymond James's latest stated price target for Haemonetics Corporation (HAE) is $78, from its action on Aug 11, 2025.
What is Raymond James's rating on HAE?
Raymond James rates HAE Outperform, a bullish rating, as of Aug 11, 2025.
When did Raymond James last change its view on HAE?
On Aug 11, 2025, Raymond James downgrades to Outperform from Strong Buy, price target $78.
How does Raymond James's HAE target compare with other analysts?
Across 4 firms with a HAE price target in the last 12 months, the median target is $106.

More HAE rating histories

All Raymond James ratingsHAE news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.